Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.

[1]  S. Kapoor,et al.  Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL , 2023, Leukemia.

[2]  Jong-Won Kim,et al.  In Vitro Evidence of Double Blockade of Asciminib with Reduced Dose of ATP-Binding Pocket Inhibitors in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation , 2022, Blood.

[3]  N. Shah,et al.  Select P-Loop Mutants in BCR::ABL1 Confer Moderate to High Degrees of Resistance to Asciminib , 2022, Blood.

[4]  W. M. Smit,et al.  Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population , 2022, Haematologica.

[5]  A. Rosell,et al.  Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia , 2022, Annals of Hematology.

[6]  J. Cortes,et al.  A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. , 2021, Blood.

[7]  G. Saglio,et al.  Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors , 2020, Leukemia.

[8]  P. Foggi,et al.  How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) , 2020, Cancer medicine.

[9]  B. Druker,et al.  Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. , 2019, The New England journal of medicine.

[10]  U. Olsson‐Strömberg,et al.  Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML). , 2019, Journal of Clinical Oncology.

[11]  Martin C. Müller,et al.  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.

[12]  Hans Bitter,et al.  The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 , 2017, Nature.

[13]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[14]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[15]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2009, Leukemia.

[16]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[17]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[18]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.